<DOC>
	<DOCNO>NCT00392925</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , effect body weight leptin , inject subcutaneously , combination pramlintide , inject subcutaneously .</brief_summary>
	<brief_title>A Study Evaluate Effect Body Weight Leptin Administered Conjunction With Pramlintide Overweight Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is obese ( Body Mass Index [ BMI ] &gt; =30kg/m^2 &lt; =35kg/m^2 ) ; overweight ( BMI &gt; =27kg/m^2 &lt; 30kg/m^2 ) abdominal obesity , base following : *waist circumference &gt; 102 cm male , *waist circumference &gt; 88 cm female Is nonsmoker ( smoke least 6 month prior study ) Consumes morning even meal day Is diagnose type 2 diabetes Is currently enrol plan enroll diet , weight loss , exercise program specific intent lose weight ( subject follow exercise regimen result stable weight maintenance least 2 month prior enrollment eligible study inclusion ) Has treat past 2 month , currently treat , expect require undergo treatment follow medication : *antiobesity agent ( prescription overthecounter ) , *antipsychotic agent , *antiepileptic agent , *antidepressant agent , *drugs directly affect gastrointestinal motility Has receive investigational drug within 30 day within period correspond 5 halflives drug , whichever great , prior study start Has previously receive treatment recombinant leptin pramlintide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>pramlintide</keyword>
	<keyword>leptin</keyword>
	<keyword>Amylin</keyword>
</DOC>